Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Diagnosis of Parvovirus B19 in Pregnancy Enhanced

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
The Iam Parvo assay is a rapid quantitative molecular assay that expands DiaSorin's diagnostic portfolio for this potentially life-threatening virus.

Parvovirus B19 (B19V) is a common childhood infection.  It causes particular concern where a pregnant woman has had contact with a B19V infected individual, or where maternal B19V infection is suspected.    During pregnancy, from as early as 6 weeks gestation, B19V can transfer from mother to foetus across the placenta. Such infection may cause hydrops fetalis, miscarriage or poor outcomes (including severe neurological disease) in surviving babies.1

Diagnosis of maternal infection relies on the detection of IgM and IgG antibodies. The presence of IgG antibodies to B19V indicates a previous infection, but it is estimated that approximately 25 to 45% of women of childbearing age do not possess these antibodies and are therefore susceptible to infection.2 

First line serology testing will indicate current active B19V infection.  However, when serological test results are negative but infection is still suspected, clinicians can rapidly confirm diagnosis using the new, highly sensitive, Iam Parvo molecular assay.  This confirmation is particularly important in the 8 - 12 week period after maternal infection, when the sensitivity of IgM antibody detection varies from 63% to 70% and serological testing alone may not give the full picture.4  Rapid diagnosis of infection allows the foetus to be monitored and appropriate care referrals to be made.

“Iam Parvo is a molecular assay that, when used together with serological testing, enhances the clinical management of B19V-complicated pregnancies,” said Paul Eros, Global Vice President Molecular, DiaSorin. “With this molecular assay launch we underpin DiaSorin’s leadership in Parvovirus B19 testing and demonstrate our commitment to providing a complete diagnostic solution for this important infectious disease. Iam Parvo is the latest addition to the unique and rapidly expanding DiaSorin Q-LAMP assay portfolio for our Liaison® Iam molecular instrument, a benchtop device which meets the needs of laboratories by providing them with a cost-effective, scaleable, molecular diagnostic solution.” 

Calibrated against the WHO standard for B19V, Iam Parvo provides exceptional time-to-result benefits when compared to PCR, with equivalent specificity.  The Liaison Iam instrument uses DiaSorin’s proprietary Q-LAMP technology.

“People should not confuse DiaSorin Q-LAMP with conventional LAMP technology”, continues Eros, “DiaSorin Q-LAMP assays provide many advantages.  They are rapid, real-time, fluorescent, quantitative/qualitative assays designed to be used for multiplexed applications, enabling amplification and detection of multiple targets in a single reaction”.    

The Iam Parvo assay is CE-IVD validated for use outside of the USA and Canada only.

For more information about the Iam Parvo assay and the Liaison Iam molecular instrument email info@ie.diasorin.com or visit www.diasorin.com

 1.    Dijkmans A.C. et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr. Opin. Obstet. Gynecol. (2012) 24:95-101. 

2.    Rohrer C., Gartner B., Sauerbrei A. et al. Seroprevalence of Parvovirus B19 in the German population.  Epidemiol. Infect. (2008), 36:1-7

3.    Bredl S., Plentz A., Wenzel J.J. et al. False negative serology in patients with acute Parvovirus B19 infection. J. Clin. Viro. (2011) 51:115-120 

4.    Enders M., Helbig S, Hunjet A. et al. Comparative evaluation of two commercial enzyme immunoassays for serodiagnosis of gestational Parvovirus B19 infection. J. Virol. Methods (2007) 146:409-413).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!